Engineered Gut Microorganisms for Hyperphenylalaninemia Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperphenylalaninemia, particularly phenylketonuria (PKU), are cumbersome, costly, and often lead to side effects, with a significant need for a more effective and reliable method to manage phenylalanine levels without restricting protein intake.
Innovation Solution
Genetically engineered microorganisms, such as bacteria, producing mutant phenylalanine ammonia lyase (PAL) and L-amino acid deaminase (LAAD), which metabolize phenylalanine into non-toxic compounds, are introduced into the gut to reduce hyperphenylalaninemia, potentially allowing for a normal diet.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current PKU treatments (protein restriction, cofactor therapy) are used, then phenylalanine levels are controlled, but quality of life deteriorates due to dietary restrictions and side effects
Solution Approach 1:
The patent introduces genetically engineered microorganisms as intermediary agents that reside in the gut and continuously metabolize phenylalanine. These microorganisms act as a biological mediator between the diet and the bloodstream, converting excess phenylalanine into non-toxic compounds without requiring dietary restriction or pharmaceutical intervention.
Solution Approach 2:
The engineered microorganisms autonomously perform the therapeutic function of phenylalanine metabolism within the gut environment. Once administered, they self-replicate and continuously carry out the metabolic conversion without requiring external control, monitoring, or patient compliance with dietary regimens.
2Reliability
If protein intake is restricted to manage phenylalanine levels, then hyperphenylalaninemia is reduced, but growth and nutrition deteriorate
Solution Approach 1:
The engineered microorganisms serve as an intermediary metabolic system in the gut that decouples phenylalanine level control from dietary protein intake. By introducing this biological mediator, patients can consume normal protein-containing diets while the microorganisms continuously convert excess phenylalanine into non-toxic metabolites, preventing accumulation.
3Reliability
If cofactor therapy is administered, then phenylalanine metabolism is improved, but cost and side effects increase
Solution Approach 1:
The patent replaces pharmaceutical cofactor therapy with genetically engineered microorganisms as a biological mediator. These microorganisms express phenylalanine-metabolizing enzymes and autonomously perform the metabolic function without requiring exogenous cofactors, thereby eliminating the need for costly monthly injections and their associated side effects.
Solution Approach 2:
The patent replaces the mechanical/pharmaceutical intervention of monthly cofactor injections with a biological system (engineered microorganisms) that performs the metabolic function continuously and autonomously within the gut, eliminating the need for repeated external interventions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered microorganisms effectively lower phenylalanine levels, offering a potentially lifelong treatment that reduces neurological damage and dietary restrictions, improving quality of life while minimizing side effects.
Implementation Method 1
Genetically engineered microorganisms, e.g., bacteria, producing mutant phenylalanine ammonia lyase (PAL) and L-amino acid deaminase (LAAD), which metabolize phenylalanine into non-toxic compounds
Data Source
AI summary
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.